On August 19, Merck and Moderna announced positive topline results from a Phase 3 trial of a treatment designed from the mutations in each patient’s tumor.
The result is easy to overstate because the companies have not yet released the numbers showing how large the difference between the groups was.
What the companies announced
INTerpath-001 is testing intismeran autogene after surgery, given with pembrolizumab (Keytruda). The comparison group receives pembrolizumab alone. Intismeran is an investigational mRNA-based individualized neoantigen therapy within the broader category often called personalized cancer vaccines.
The August 19 announcement says the trial enrolled 1,137 patients with completely resected stage IIB-IV cutaneous melanoma who had not received prior systemic therapy. At a prespecified interim analysis, the companies said the combination met:
the primary endpoint of recurrence-free survival, which tracks recurrence or death; and
a key secondary endpoint of distant metastasis-free survival, which tracks distant spread or death.
The companies described both improvements as statistically significant and clinically meaningful compared with pembrolizumab alone. They also reported no new safety signals and said the study will continue to evaluate other endpoints, including overall survival.
According to the announcement, this is the first positive Phase 3 result for an individualized neoantigen therapy and for an mRNA-based cancer therapy.
What is not public yet
The announcement does not include the Phase 3 hazard ratios, confidence intervals, event counts, survival curves, subgroup results, or detailed safety tables. Those numbers are needed to judge the size and certainty of the benefit.
The companies say they plan to present the data at an international medical meeting and share it with regulators. Until that happens, this remains a company-reported topline result, not a peer-reviewed Phase 3 publication or an FDA decision.
ClinicalTrials.gov still lists the study as “active, not recruiting” and shows no posted results as of September 1. The new information comes from the company announcement, not from a results submission on the registry.
How an individualized neoantigen therapy works
The National Cancer Institute defines a neoantigen as a new protein that forms on cancer cells when certain mutations occur in tumor DNA. Researchers are studying neoantigens as targets for vaccines and other immunotherapies. The NCI’s cancer-treatment-vaccine overview explains the broader idea.
For intismeran specifically, Merck and Moderna say the therapy is designed using a patient’s tumor sample to identify a tumor-specific mutational fingerprint. It uses synthetic mRNA encoding up to 34 selected neoantigens with the goal of generating a tumor-specific immune response. Other products and studies may use different methods.
What came before this result
A June 1, 2026 Journal of Clinical Oncology article reported five-year follow-up from the randomized Phase 2b KEYNOTE-942 study. In 157 participants with resected stage IIIB-IV cutaneous melanoma, outcomes continued to favor intismeran plus pembrolizumab over pembrolizumab alone for recurrence-free and distant-metastasis-free survival. The paper labels the five-year analyses as descriptive. Read the article record on PubMed.
What this does and does not show
The announcement marks a Phase 3 milestone for this specific combination in melanoma treated after surgery, but the effect sizes and detailed results are not yet public. It does not show that every personalized cancer vaccine works, that the treatment works across cancer types, that it treats active metastatic disease, or that the vaccine works by itself.
Three things to watch next
The size of the benefit. The hazard ratios, confidence intervals, event counts, and survival curves will show how far apart the groups were and how precise the estimate is.
The full safety and overall-survival results. “No new safety signals” is a topline statement, not a substitute for the detailed adverse-event data. Overall-survival follow-up is continuing.
The path from data to a regulatory decision. A positive trial announcement is not an approval. A medical-meeting presentation, fuller publication, and any regulator filings or decisions remain separate events.
The obvious question is whether a patient can get intismeran now. None of this makes it available through FDA expanded access, a separate pathway considered in limited circumstances that does not guarantee product availability, access, or benefit.
What to expect on Tuesdays
Each Tuesday, ImmunaPath explains one development in personalized cancer vaccines, computational oncology, or the trial and access pathways around them: what changed, what did not, and where to read the source.
If this helped, forward it to one person who would value a careful explanation.
— Alex
ImmunaPath provides educational information, not medical advice, diagnosis, treatment, eligibility determinations, or access coordination. Always discuss treatment and trial decisions with your oncologist or qualified healthcare team.